Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis

Yoh Takekuma, Toru Takenaka, Masami Kiyokawa, Koujiro Yamazaki, Hiroshi Okamoto, Akira Kitabatake, Hiroyuki Tsutsui, Mitsuru Sugawara

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

In our previous study it was observed that the frequencies of UGT1A1*6, UGT2B7*3 and CYP2D6*10 in patients who have a low level ability of glucuronidation were significantly higher than those in patients with a high level of ability of glucuronidation. The same tendency was found in the frequency of CYP2D6*5, though there was no significant difference. The purpose of this study was to evaluate the effects of the polymorphism on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Population pharmacokinetic analysis was performed using 373 plasma concentrations from 41 patients with chronic heart failure or angina pectoris. A one compartment pharmacokinetic model with first-order absorption (for oral dosing) was used to describe the concentration-versus-time data for carvedilol. We examined the effects of various clinical and genetic covariables in the regression models for clearance and volume of distribution. The results suggested that the factors of interindividual variation for carvedilol clearance were creatinine clearance and polymorphisms of UGT2B7 and CYP2D6 in the Japanese population with heart disease. It was estimated that UGT2B7*3 decreased the clearance of carvedilol by 37%, but UGT2B7*2 did not show any effect. Clearance in the patients who have intermediate activity of CYP2D6 was decreased by 39%.

Original languageEnglish
Pages (from-to)537-542
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 1 2007
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP2D6
Pharmacokinetics
Aptitude
Enzymes
Population
Angina Pectoris
Heart Diseases
Creatinine
Heart Failure
carvedilol

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. / Takekuma, Yoh; Takenaka, Toru; Kiyokawa, Masami; Yamazaki, Koujiro; Okamoto, Hiroshi; Kitabatake, Akira; Tsutsui, Hiroyuki; Sugawara, Mitsuru.

In: Biological and Pharmaceutical Bulletin, Vol. 30, No. 3, 01.03.2007, p. 537-542.

Research output: Contribution to journalArticle

Takekuma, Yoh ; Takenaka, Toru ; Kiyokawa, Masami ; Yamazaki, Koujiro ; Okamoto, Hiroshi ; Kitabatake, Akira ; Tsutsui, Hiroyuki ; Sugawara, Mitsuru. / Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. In: Biological and Pharmaceutical Bulletin. 2007 ; Vol. 30, No. 3. pp. 537-542.
@article{a9e7829d2b334090859309d8b5cb75e6,
title = "Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis",
abstract = "In our previous study it was observed that the frequencies of UGT1A1*6, UGT2B7*3 and CYP2D6*10 in patients who have a low level ability of glucuronidation were significantly higher than those in patients with a high level of ability of glucuronidation. The same tendency was found in the frequency of CYP2D6*5, though there was no significant difference. The purpose of this study was to evaluate the effects of the polymorphism on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Population pharmacokinetic analysis was performed using 373 plasma concentrations from 41 patients with chronic heart failure or angina pectoris. A one compartment pharmacokinetic model with first-order absorption (for oral dosing) was used to describe the concentration-versus-time data for carvedilol. We examined the effects of various clinical and genetic covariables in the regression models for clearance and volume of distribution. The results suggested that the factors of interindividual variation for carvedilol clearance were creatinine clearance and polymorphisms of UGT2B7 and CYP2D6 in the Japanese population with heart disease. It was estimated that UGT2B7*3 decreased the clearance of carvedilol by 37{\%}, but UGT2B7*2 did not show any effect. Clearance in the patients who have intermediate activity of CYP2D6 was decreased by 39{\%}.",
author = "Yoh Takekuma and Toru Takenaka and Masami Kiyokawa and Koujiro Yamazaki and Hiroshi Okamoto and Akira Kitabatake and Hiroyuki Tsutsui and Mitsuru Sugawara",
year = "2007",
month = "3",
day = "1",
doi = "10.1248/bpb.30.537",
language = "English",
volume = "30",
pages = "537--542",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "3",

}

TY - JOUR

T1 - Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis

AU - Takekuma, Yoh

AU - Takenaka, Toru

AU - Kiyokawa, Masami

AU - Yamazaki, Koujiro

AU - Okamoto, Hiroshi

AU - Kitabatake, Akira

AU - Tsutsui, Hiroyuki

AU - Sugawara, Mitsuru

PY - 2007/3/1

Y1 - 2007/3/1

N2 - In our previous study it was observed that the frequencies of UGT1A1*6, UGT2B7*3 and CYP2D6*10 in patients who have a low level ability of glucuronidation were significantly higher than those in patients with a high level of ability of glucuronidation. The same tendency was found in the frequency of CYP2D6*5, though there was no significant difference. The purpose of this study was to evaluate the effects of the polymorphism on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Population pharmacokinetic analysis was performed using 373 plasma concentrations from 41 patients with chronic heart failure or angina pectoris. A one compartment pharmacokinetic model with first-order absorption (for oral dosing) was used to describe the concentration-versus-time data for carvedilol. We examined the effects of various clinical and genetic covariables in the regression models for clearance and volume of distribution. The results suggested that the factors of interindividual variation for carvedilol clearance were creatinine clearance and polymorphisms of UGT2B7 and CYP2D6 in the Japanese population with heart disease. It was estimated that UGT2B7*3 decreased the clearance of carvedilol by 37%, but UGT2B7*2 did not show any effect. Clearance in the patients who have intermediate activity of CYP2D6 was decreased by 39%.

AB - In our previous study it was observed that the frequencies of UGT1A1*6, UGT2B7*3 and CYP2D6*10 in patients who have a low level ability of glucuronidation were significantly higher than those in patients with a high level of ability of glucuronidation. The same tendency was found in the frequency of CYP2D6*5, though there was no significant difference. The purpose of this study was to evaluate the effects of the polymorphism on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Population pharmacokinetic analysis was performed using 373 plasma concentrations from 41 patients with chronic heart failure or angina pectoris. A one compartment pharmacokinetic model with first-order absorption (for oral dosing) was used to describe the concentration-versus-time data for carvedilol. We examined the effects of various clinical and genetic covariables in the regression models for clearance and volume of distribution. The results suggested that the factors of interindividual variation for carvedilol clearance were creatinine clearance and polymorphisms of UGT2B7 and CYP2D6 in the Japanese population with heart disease. It was estimated that UGT2B7*3 decreased the clearance of carvedilol by 37%, but UGT2B7*2 did not show any effect. Clearance in the patients who have intermediate activity of CYP2D6 was decreased by 39%.

UR - http://www.scopus.com/inward/record.url?scp=33847685292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847685292&partnerID=8YFLogxK

U2 - 10.1248/bpb.30.537

DO - 10.1248/bpb.30.537

M3 - Article

C2 - 17329852

AN - SCOPUS:33847685292

VL - 30

SP - 537

EP - 542

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 3

ER -